|Publication number||USRE43311 E1|
|Application number||US 11/707,233|
|Publication date||10 Apr 2012|
|Filing date||14 Feb 2007|
|Priority date||29 Aug 1997|
|Also published as||CA2302162A1, CA2302162C, DE69832180D1, DE69832180T2, EP1009296A1, EP1009296B1, US6156061, US6425914, WO1999009895A1|
|Publication number||11707233, 707233, US RE43311 E1, US RE43311E1, US-E1-RE43311, USRE43311 E1, USRE43311E1|
|Inventors||Michael P. Wallace, Mehran Bashiri, Chad C. Roue|
|Original Assignee||Stryker Corporation, Stryker Nv Operations Limited|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (78), Non-Patent Citations (12), Referenced by (2), Classifications (26), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation reissue of U.S. reissue application Ser. No. 10/900,901, filed on Jul. 27, 2004 (now abandoned), which is a reissue application of U.S. application Ser. No. 09/668,033, filed on Sep. 21, 2000, now U.S. Pat. No. 6,425,914, which is a continuation of U.S. patent application Ser. No. 08/920,526, filed on Aug. 29, 1997, now U.S. Pat. No. 6,156,061 the entirety of which is hereby incorporated by reference.
This invention is an implant for placement in the human body and an assembly for so placing that implant. Most desirably, it is an implant for use in the vasculature of the human body and is used to occlude some space in that vasculature as a portion of a treatment regimen. The implant itself is preferably a component of a deployment device using an electrolytically severable joint. The implant component is at least partially covered with a highly resistive or insulative covering. The highly resistive or insulative layer or covering appears to enhance the susceptibility of the electrolytic joint to quick erosion and thus detachment of the implant. Although the implant itself is preferably a vaso-occlusive device, it may instead be a stent, a vena cava filter, or other implant which may be installed in this manner. The implant may be independently coated with insulative or resistive material or may be formed using a material with such as tantalum, which forms such an insulator or resistor in situ.
Implants may be placed in the human body for a wide variety of reasons. For instance, stents are placed in a number of different lumens in the body. They may be placed in arteries to cover vascular lesions or to provide patency to the vessel. Stents are also placed in biliary ducts to prevent them from kinking or collapsing. Grafts may be used with stents to promote growth of endotbelial tissue within those vessels.
Vena cava filters are implanted in the body, typically in the vena cava, to catch thrombus which are sloughed off from other sites within the body and which may be in the blood passing through the chosen site.
Vaso-occlusive devices or implants are used for a wide variety of reasons. They are often used for treatment of intra-vascular aneurysms. This is to say that the treatment involves the placement of a vaso-occlusive device in an aneurysm to cause the formation of a clot and eventually of a collagenous mass containing the vaso-occlusive device. These occlusions seal and fill the aneurysm thereby preventing the weakened wall of the aneurysm from being exposed to the pulsing blood pressure of the open vascular lumen.
Treatment of aneurysms in this fashion is significant improvement over the surgical method typically involved. The surgical or extravascular approach is a common treatment of intra-cranial berry aneurysm; it is straightforward but fairly traumatic. The method involves removing of portion of the cranium and locating the aneurysm. The neck of the aneurysm is closed typically by applying a specially sized clip to the neck of the aneurysm. The surgeon may choose to perform a suture ligation of the neck or wrap the entire aneurysm. Each of these procedures is performed by an very intrusive invasion into the body and is performed from the outside of the aneurysm or target site. General anesthesia, craniotomy, brain retraction, and a placement of clip around the neck of the aneurysm all are traumatic. The surgical procedure is often delayed while waiting for the patient to stabilize medically. For this reason, many patients die from the underlying disease prior to the initiation of the surgical procedure.
Another procedure—the extra-intravascular approach—involves surgically exposing or stereotaxically reaching an aneurysm with a probe. The wall of the aneurysm is perforated from the outside and various techniques are used to occlude the interior of the aneurysm to prevent its rebleeding. The techniques used to occlude the aneurysm include electro-thrombosis, adhesive embolization, hoghair embolization, and ferromagnetic thrombosis. These procedures are discussed in U.S. Pat. No. 5,122,136 to Guglielmi et al., the entirety of which is incorporated by reference.
Guglielmi et al. further describes an endovascular procedure which is at once the most elegant and least invasive. The procedure described in that patent includes a step in which the interior of the aneurysm is entered by the use of guidewire such as those in Engelson, U.S. Pat. No. 4,884,579 and a catheter as in Engelson, U.S. Pat. No. 4,739,768. These patents described devices utilizing guidewires and catheters which allow access to aneurysms from remote parts of the body. Typically, these catheters enter the vasculature through an artery in the groin. The Guglielmi et al system uses catheters and guidewires which have a very flexible distal regions and supporting midsections which allow the combinations to be steerable to the region of the aneurysm. That is to say that the guidewire is first steered for a portion of the route to the aneurysm and the catheter is slid up over that guidewire until it reaches a point near the distal end of the guidewire. By steps, the catheter and guidewire are then placed at the mouth of the aneurysm. The catheter is introduced into the aneurysm and vaso-occlusive or embolism-forming devices may be delivered through the lumen.
Various vaso-occlusive devices are introduced through the noted microcatheters to close the aneurysm site. In some instances, a small balloon may be introduced into the aneurysm where it is inflated, detached, and left to occlude the aneurysm. Balloons are becoming less in favor because of the difficulty in introducing the balloon into the aneurysm sac, the possibility of aneurysm rupture due to over-inflation of the balloon within the aneurysm, and the inherent risk associated with the traction produced when detaching the balloon.
Another desirable embolism-forming device which may be introduced into aneurysm using end of vascular placement procedure is found in U.S. Pat. No. 4,994,069 to Ritchart et al. In that patent are described various devices—typically platinum/tungsten alloy coils having very small diameters—which may be introduced into the aneurysm through a catheter such as those described in the Engelson patents above. These coils are often made of wire having a diameter of 2-6 mils. The coil diameter is often 10-30 mils. These soft, flexible coils, may be of any length desirable and appropriate for the site to be occluded. After these vaso-occlusive coils are placed in, e.g., a berry aneurysm, they first cause a formation of an embolic mass. This initial mass is shortly thereafter complemented with a collagenous material which significantly lessens the potential for aneurysm rupture.
There are variety of other vaso-occlusive devices, typically coils which may be delivered to the vascular site in a variety of ways, e.g., by mechanically detaching them from the delivery device. A significant number of these devices are described in patents owned by Target Therapeutics, Inc. For instance:
U.S. Pat. No. 5,234,437, to Sepetka shows a method of unscrewing a helically wound coil from a pusher having interlocking surfaces.
U.S. Pat. No. 5,250,071, to Palermo shows an embolic coil assembly using interlocking clasps both on the pusher and on the embolic coil.
U.S. Pat. No. 5,261,916, to Engelson shows a combination pusher/vaso-occlusive coil assembly joined by an interlocking ball and keyway type coupling.
U.S. Pat. No. 5,304,195, to Twyford et al., shows a pusher/vaso-occlusive coil assembly having a fixed proximally extending wire carrying a ball on its proximal end and a pusher having a similar end which two tips are interlocked and disengaged when expelled from the distal tip of the catheter.
U.S. Pat. No. 5,312,415, to Palermo shows a method for discharging numerous coils from a single pusher by using a guidewire which has a section capable of interconnecting with the interior of a helically wound coil.
U.S. Pat. No. 5,350,397, to Palermo et al. shows a pusher having a throat at its distal end and a pusher through its axis. The pusher throat holds onto the end of an embolic coil and releases that coil upon pushing the axially placed pusher wire against member found on the proximal end of the vaso-occlusive coil.
Other mechanically detachable embolism forming devices are known in the art.
Each of the patents listed herein is specifically incorporated by reference.
Guglielmi et al. shows an embolism forming device and procedure for using that device which, instead of a mechanical joint, uses an electrolytically severable joint. Specifically, Guglielmi et al. desirably places a finely wound platinum coil into a vascular cavity such as an aneurysm. The coil is delivered endovascularly using a catheter such as those described above. After placement in the aneurysm, the coil is severed from its insertion core wire by the application of a small electric current to that core wire. The deliverable coils are said to be made of a platinum material. They may be 1-50 cm or longer as is necessary. Proximal of the embolic coil, as noted above, is a core wire which is typically stainless steel. The core wire is used to push the platinum embolic coil into vascular site to be occluded.
Other variations of the Guglielmi et al. technology are found in U.S. Pat. No. 5,354,295.
None of the references described above teach or suggests an implant having a highly resistive or insulative layer on at least a portion of its exterior surface which is flexibly attached to an electrolytically severable delivery joint.
This invention is an implant which is at least partially coated with an insulative material. The implant may be a vaso-occlusive device, stent, vena cava filter, or any other implant which may be delivered via a catheter. Desirably, the device includes a core wire having a distal tip, which distal tip may be introduced into the selected site. The core wire is attached to the distal tip or implant in such a way that it may be electrolytically detached by application of a current to the core wire.
The improvement involves the use of an insulative or highly resistive covering on at least a portion of the implant. The resistive covering is preferably one which is formed in situ from the material making up the implant. This insulative or highly resistive layer appears to focus the current flow through the sacrificial electrolytic joint and thereby improves the rate at which detachment occurs.
As noted above, the Guglielmi et al. system for deploying an implant into the human body uses a core wire, an electrolytic sacrificial joint, and the implant to be deployed. A power supply is needed to provide power for electrolysis of the joint. The core wire is typically insulated on its outer surface from near the proximal end of the wire to the electrolytic sacrificial joint. The implant typically forms a portion of the circuit through the body. This invention substantially removes the implant itself from that circuit, thereby apparently focusing the current flow at the electrolytic joint where it is needed.
The most proximal end of core wire (110) is also left bare so that power supply (116) may be attached. The other pole of the power supply (116) is typically attached to a patch (118). The patch (118) is placed on the skin to complete the circuit from the power supply (116), through the core wire (110), through electrolytic joint (112), through the ionic solution in the body, and back to a patch (118) to the power supply (116). Other return routes may be used as the designer sees fit.
The coil making up this variation of the invention is generally of a diameter in the range of 0.00025 inches and 0.006 inches. Wire of such diameter is wound into a primary form having a diameter of between 0.003 and 0.025 inches. For most neurovascular indications, the preferable primary coil diameter is preferably between 0.008 and 0.018 inches.
The axial length of the primary coil will usually fall in the range of 0.5 to 100 cm, more usually 2.0 to 40 cm. Depending upon usage, the coil may well have 10-75 turns per centimeter, preferably 10-40 turns per centimeter. All of the dimensions here are provided only as guidelines and are not critical to the invention. However, only dimensions suitable for use in occluding sites within the human body are included in the scope of this invention.
Central to this invention is the provision of a highly resistive or insulative layer or covering on at least a portion of implant (120). Without wishing to be bound by theory, it is believed that the covering on implant (120) prevents or lessens current flow through the implant (120) itself and concentrates the current flow through the electrolytic joint (112). Preferably, implant (120) has at least 95% of its surface area covered with the layer. The layer, which will be discussed in more detail below, should not be of a type which interferes with the formation of the occlusion, when the implant is an occlusion device. It similarly should not interfere with the other functions inherent with this specific type of implant placed distally of the electrolytically severable joint (112). That is to say that, for instance, the insulative layer should not interfere with the function of a stent by, e.g., being thrombogenic.
The implant may be made of other insulation-forming materials or oxide forming materials including metals such as zirconium, its alloys, and related materials which form or may be made to form exterior resistive layers by, e.g., nitriding, or the like, preferably but not necessarily in situ.
Although the core (142) may be completely made of a insulation forming material as is shown in
Although the preferred variation of the invention is that found in
When the implant is a vaso-occlusive device, the shape of the device may be any of a number of suitable overall shapes to promote occlusion of the selected interior body space. In particular, when the implant is a helical coil, many shapes are known for treatment of particular abnormalities.
Each of the catheters described herein may also have attached fibrous materials to increase thrombogenicity.
The stent shown in
After the thrombus (218) has been formed and the aneurysm occluded, vaso-occlusive device (208) is detached from core wire (212) by electrolytic disintegration of sacrificial link (210).
After sacrificial link (210) is at least mostly dissolved by electrolytic action, typically in less than two minutes and most often in less than one minute, the core wire (212) and catheter (202) are removed from vessel (200) leaving aneurysm (206) occluded as shown in
This procedure is practiced under fluoroscopic control either with general or local anesthesia. A transfemoral catheter is typically used to treat cerebral aneurysms and is usually introduced at the groin. When the vaso-occlusive device (208) is insulated or covered with a highly resistive material as is contemplated this invention, it is not affected by electrolysis. When the core wire (212) and the pertinent portions of the supporting coils at the distal tip of the core wire (when utilized) are adequately coated with insulating coverings, only the exposed portion of the sacrificial link (210) is affected by the electrolysis.
Many alterations and modifications may be made by those having ordinary skill in this art without departing from the spirit and scope of the invention. The illustrative embodiments have been used only for the purposes of clarity and should not be taken as limiting the invention as defined by the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4010759||29 Aug 1975||8 Mar 1977||Vitatron Medical B.V.||Insulated, corrosion resistant medical electronic devices and method for producing same|
|US4739768||2 Jun 1986||26 Apr 1988||Target Therapeutics||Catheter for guide-wire tracking|
|US4884579||18 Apr 1988||5 Dec 1989||Target Therapeutics||Catheter guide wire|
|US4945342||5 Oct 1988||31 Jul 1990||Instit Straumann||Electrical cable for performing stimulations and/or measurements inside a human or animal body and method of manufacturing the cable|
|US4994069||2 Nov 1988||19 Feb 1991||Target Therapeutics||Vaso-occlusion coil and method|
|US5122136||13 Mar 1990||16 Jun 1992||The Regents Of The University Of California||Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5226911 *||2 Oct 1991||13 Jul 1993||Target Therapeutics||Vasoocclusion coil with attached fibrous element(s)|
|US5234437||12 Dec 1991||10 Aug 1993||Target Therapeutics, Inc.||Detachable pusher-vasoocclusion coil assembly with threaded coupling|
|US5250071||22 Sep 1992||5 Oct 1993||Target Therapeutics, Inc.||Detachable embolic coil assembly using interlocking clasps and method of use|
|US5261916||12 Dec 1991||16 Nov 1993||Target Therapeutics||Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling|
|US5304195||21 Jan 1993||19 Apr 1994||Target Therapeutics, Inc.||Detachable pusher-vasoocclusive coil assembly with interlocking coupling|
|US5304200||13 Jan 1993||19 Apr 1994||Cordis Corporation||Welded radially expandable endoprosthesis and the like|
|US5312415||22 Sep 1992||17 May 1994||Target Therapeutics, Inc.||Assembly for placement of embolic coils using frictional placement|
|US5350397||13 Nov 1992||27 Sep 1994||Target Therapeutics, Inc.||Axially detachable embolic coil assembly|
|US5354295||24 Feb 1992||11 Oct 1994||Target Therapeutics, Inc.||In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5356433||3 Nov 1993||18 Oct 1994||Cordis Corporation||Biocompatible metal surfaces|
|US5382259 *||26 Oct 1992||17 Jan 1995||Target Therapeutics, Inc.||Vasoocclusion coil with attached tubular woven or braided fibrous covering|
|US5423829||3 Nov 1993||13 Jun 1995||Target Therapeutics, Inc.||Electrolytically severable joint for endovascular embolic devices|
|US5423849 *||15 Jan 1993||13 Jun 1995||Target Therapeutics, Inc.||Vasoocclusion device containing radiopaque fibers|
|US5522836||27 Jun 1994||4 Jun 1996||Target Therapeutics, Inc.||Electrolytically severable coil assembly with movable detachment point|
|US5540680||23 Sep 1994||30 Jul 1996||The Regents Of The University Of California||Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5549624||24 Jun 1994||27 Aug 1996||Target Therapeutics, Inc.||Fibered vasooclusion coils|
|US5569245||17 Oct 1994||29 Oct 1996||The Regents Of The University Of California||Detachable endovascular occlusion device activated by alternating electric current|
|US5582619||30 Jun 1995||10 Dec 1996||Target Therapeutics, Inc.||Stretch resistant vaso-occlusive coils|
|US5609629||7 Jun 1995||11 Mar 1997||Med Institute, Inc.||Coated implantable medical device|
|US5624449||28 Apr 1995||29 Apr 1997||Target Therapeutics||Electrolytically severable joint for endovascular embolic devices|
|US5624461||6 Jun 1995||29 Apr 1997||Target Therapeutics, Inc.||Three dimensional in-filling vaso-occlusive coils|
|US5634942||19 Apr 1995||3 Jun 1997||B. Braun Celsa||Assembly comprising a blood filter for temporary or definitive use and a device for implanting it|
|US5643254||21 Nov 1995||1 Jul 1997||Target Therapeutics, Inc.||Endovascular embolic device detachment detection method|
|US5645082||27 Jan 1994||8 Jul 1997||Cardima, Inc.||Intravascular method and system for treating arrhythmia|
|US5645558 *||20 Apr 1995||8 Jul 1997||Medical University Of South Carolina||Anatomically shaped vasoocclusive device and method of making the same|
|US5649951||6 Jun 1995||22 Jul 1997||Smith & Nephew Richards, Inc.||Zirconium oxide and zirconium nitride coated stents|
|US5733294||28 Feb 1996||31 Mar 1998||B. Braun Medical, Inc.||Self expanding cardiovascular occlusion device, method of using and method of making the same|
|US5735896 *||6 Apr 1995||7 Apr 1998||Biotronik||Biocompatible prosthesis|
|US5743905||27 Feb 1996||28 Apr 1998||Target Therapeutics, Inc.||Partially insulated occlusion device|
|US5759161||26 Apr 1996||2 Jun 1998||Kaneka Medix Corporation||Medical wire and method for leaving implanted devices|
|US5776178 *||21 Feb 1996||7 Jul 1998||Medtronic, Inc.||Medical electrical lead with surface treatment for enhanced fixation|
|US5782910 *||6 Jun 1996||21 Jul 1998||Smith & Nephew, Inc.||Cardiovascular implants of enhanced biocompatibility|
|US5800454||17 Mar 1997||1 Sep 1998||Sarcos, Inc.||Catheter deliverable coiled wire thromboginic apparatus and method|
|US5824077 *||6 Jun 1995||20 Oct 1998||Schneider (Usa) Inc||Clad composite stent|
|US5830230 *||7 Mar 1997||3 Nov 1998||Micro Therapeutics, Inc.||Method of intracranial vascular embolotherapy using self anchoring coils|
|US5855578||14 Feb 1997||5 Jan 1999||The Regents Of The University Of California||Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5873904 *||24 Feb 1997||23 Feb 1999||Cook Incorporated||Silver implantable medical device|
|US5891128||20 Dec 1996||6 Apr 1999||Target Therapeutics, Inc.||Solderless electrolytically severable joint for detachable devices placed within the mammalian body|
|US5891130||18 Mar 1994||6 Apr 1999||Target Therapeutics, Inc.||Axially detachable embolic coil assembly|
|US5895385||6 Nov 1997||20 Apr 1999||The Regents Of The University Of California||Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5895391||27 Sep 1996||20 Apr 1999||Target Therapeutics, Inc.||Ball lock joint and introducer for vaso-occlusive member|
|US5911717||17 Mar 1997||15 Jun 1999||Precision Vascular Systems, Inc.||Catheter deliverable thrombogenic apparatus and method|
|US5916235||13 Aug 1997||29 Jun 1999||The Regents Of The University Of California||Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities|
|US5919187||15 Sep 1995||6 Jul 1999||The Regents Of The University Of California||Method and apparatus for endovascular thermal thrombosis and thermal cancer treatment|
|US5925037||6 Oct 1997||20 Jul 1999||The Regents Of The University Of California|
|US5925060||13 Mar 1998||20 Jul 1999||B. Braun Celsa||Covered self-expanding vascular occlusion device|
|US5925062||26 Sep 1997||20 Jul 1999||Board Of Regents, The University Of Texas System||Intravascular device|
|US5928226||6 Oct 1997||27 Jul 1999||The Regents Of The University Of California|
|US5941888||18 Feb 1998||24 Aug 1999||Target Therapeutics, Inc.||Vaso-occlusive member assembly with multiple detaching points|
|US5944714||6 Oct 1997||31 Aug 1999||The Regents Of The University Of California|
|US5947962||6 Oct 1997||7 Sep 1999||The Regents Of The University Of California||Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries veins aneurysms vascular malformations and arteriovenous fistulas|
|US5947963||6 Oct 1997||7 Sep 1999||The Regents Of The University Of California|
|US5976126||6 Oct 1997||2 Nov 1999||The Regents Of The University Of California||Endovascular electrolytically detachable wire and tip formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas|
|US5976131 *||18 Jun 1996||2 Nov 1999||The Regents Of The University At California||Detachable endovascular occlusion device activated by alternating electric current|
|US6010498||6 Oct 1997||4 Jan 2000||The Regents Of The University Of California|
|US6083220 *||9 May 1996||4 Jul 2000||The Regents Of The University Of California|
|US6156061 *||29 Aug 1997||5 Dec 2000||Target Therapeutics, Inc.||Fast-detaching electrically insulated implant|
|US6174329 *||22 Aug 1996||16 Jan 2001||Advanced Cardiovascular Systems, Inc.||Protective coating for a stent with intermediate radiopaque coating|
|US6425914 *||21 Sep 2000||30 Jul 2002||Target Therapeutics, Inc.||Fast-detaching electrically insulated implant|
|EP0719522A1||27 Dec 1995||3 Jul 1996||Target Therapeutics, Inc.||Solderless electrolytically severable joint for detachable devices placed withinthe mammalian body|
|EP0754435A1||28 Jun 1996||22 Jan 1997||Target Therapeutics, Inc.||Stretch-resistant vaso-occlusive coils|
|EP0826342A1||20 Aug 1997||4 Mar 1998||Target Therapeutics, Inc.||Electrolytically deployable braided vaso-occlusion device|
|JP2641715B2||Title not available|
|JPH07265431A||Title not available|
|JPH09108229A||Title not available|
|JPH09168547A||Title not available|
|JPH09232871A||Title not available|
|WO1997023169A1||19 Dec 1996||3 Jul 1997||Muta M Issa||Resectoscope electrode assembly with simultaneous cutting and coagulation|
|WO1997048351A1||19 Jun 1997||24 Dec 1997||Univ South Carolina||In situ formable and self-forming intravascular flow modifier (ifm), catheter and ifm assembly, and method for deployment of same|
|WO1998002100A1||15 Jul 1997||22 Jan 1998||Anson Medical Ltd||Surgical implants and delivery systems therefor|
|WO1998004198A1||21 Jul 1997||5 Feb 1998||Richard J Greff||Method and apparatus for intravascular embolization|
|WO1998004315A1||18 Jun 1997||5 Feb 1998||Micro Therapeutics Inc||Method and apparatus for intravascular embolization|
|1||CA Office Action, dated Jul. 25, 2005 for related CA application serial No. 2,302,162, Applicant Applicant Boston Scientific Limited (4 pages).|
|2||CA Response to Office Action, dated Oct. 16, 2006 for related CA application serial No. 2,302,162, Applicant Boston Scientific Limited (8 pages).|
|3||EP Amendment and Response to Office Action, dated Feb. 28, 2005 for related EP application serial No. 98945802.1, Applicant Boston Scientific Limited (17 pages).|
|4||EP Amendment and Response to Office Action, dated Jun. 10, 2004 for related EP application serial No. 98945802.1, Applicant Boston Scientific Limited (15 pages).|
|5||EP Notice of Allowance, dated May 3, 2005 for related EP application serial No. 98945802.1, Applicant Boston Scientific Limited (6 pages).|
|6||EP Office Action, dated Aug. 23, 2004 for related EP application serial No. 98945802.1, Applicant Boston Scientific Limited (4 pages).|
|7||EP Office Action, dated Dec. 11, 2003 for related EP application serial No. 98945802.1, Applicant Boston Scientific Limited (3 pages).|
|8||JP Office Action with English translation, dated Jun. 7, 2007 for related JP application serial No. 2000-507292, Applicant Boston Scientific Limited (14 pages).|
|9||JP Response to Office Action, dated Sep. 26, 2007 for related JP application serial No. 2000-507292, Applicant Boston Scientific Limited (17 pages).|
|10||PCT International Preliminary Examination Report (IPER), form PCT/IPEA/416, dated Nov. 8, 1999, for related International Application No. PCT/US98/17978, Applicant Scimed Life Systems, Inc (8 pages).|
|11||PCT International Search Report (ISR), form PCT/ISA/210 & 220, dated Dec. 18, 1998 for related International Application No. PCT/US98/17978, Applicant Scimed Life Systems, Inc. (8 pages).|
|12||PCT Written Opinion, form PCT/IPEA/408, dated Aug. 3, 1999, for related International Application No. PCT/US98/17978, Applicant Scimed Life Systems, Inc (9 pages).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US9011482||28 May 2014||21 Apr 2015||Tw Medical Technologies, Llc||Vaso-occlusive devices including a friction element and methods of use|
|US9060777||28 May 2014||23 Jun 2015||Tw Medical Technologies, Llc||Vaso-occlusive devices and methods of use|
|U.S. Classification||623/1.11, 606/200, 606/195|
|International Classification||A61B17/12, A61M29/00, A61F2/88, A61F2/02, A61F2/01, A61F2/90|
|Cooperative Classification||A61B17/12154, A61F2/88, A61B17/12145, A61F2/95, A61B2017/12063, A61B17/12113, A61F2002/011, A61B17/1215, A61B17/12022, A61F2/90, A61F2/01|
|European Classification||A61F2/95, A61B17/12P, A61B17/12P7C5, A61B17/12P5B1, A61B17/12P7C1, A61B17/12P7C3|
|15 Mar 2011||AS||Assignment|
Owner name: STRYKER CORPORATION, MICHIGAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TARGET THERAPEUTICS, INC.;REEL/FRAME:025957/0313
Effective date: 20110103
Owner name: STRYKER NV OPERATIONS LIMITED, IRELAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TARGET THERAPEUTICS, INC.;REEL/FRAME:025957/0313
Effective date: 20110103
|8 Jan 2014||FPAY||Fee payment|
Year of fee payment: 12
|23 Nov 2015||AS||Assignment|
Owner name: STRYKER EUROPEAN HOLDINGS I, LLC, MICHIGAN
Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER MEDTECH LIMITED;REEL/FRAME:037153/0241
Effective date: 20151013
Owner name: STRYKER MEDTECH LIMITED, MALTA
Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER NV OPERATIONS LIMITED;REEL/FRAME:037153/0034
Effective date: 20151013